Interleukin 4-590T/C polymorphism and susceptibility to leprosy

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 12, 2011, Pages 877-881

  Yang, Degang ^a   Song, Haihan ^b   Xu, Weimin ^a   Long, Heng ^c   Shi, Chao ^a   Jing, Zhichun ^a   Song, Weiguo ^d   Pei, Bin ^a  

^a Shanghai Skin Disease Hospital   (China)

^b UNIVERSITY OF TORONTO   (Canada)

^c Wenshan Institute of Dermatology and Venereology   (China)

^d Shandong Academy of Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INFANT; LEPROSY; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; SCHOOL CHILD;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; INFANT, NEWBORN; INTERLEUKIN-4; LEPROSY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; YOUNG ADULT;

EID: 84055190867     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0032     Document Type: Article

References (46)

1. Caughey AB, Washington AE, Gildengorin V, Kuppermann M (2004) Assessment of demand for prenatal diagnostic testing using willingness to pay. Obstet Gynecol 103:539-545. (Pubitemid 40459071)
2. Chao S, Roberts JS, Marteau TM, et al. (2008) Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL study. Alzheimer Dis Assoc Disord 22:94-97. (Pubitemid 351651404)
3. Farrer LA, Cupples LA, Haines JL, et al. (1997) Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease: A meta-analysis. JAMA 278:1349-1356. (Pubitemid 27449696)
4. Frew EJ, Wolstenholme JL, Whynes DK (2004) Comparing willingness-to-pay: bidding game format versus open-ended and payment scale formats. Health Policy 68:289-298. (Pubitemid 38534457)
5. Green RC, Cupples LA, Go R, et al. (2002) Risk of dementia among White and African American relatives of patients with Alzheimer's disease. JAMA 287:329-336. (Pubitemid 34251966)
6. Green RC, Roberts JS, Cupples LA, et al. (2009) Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 361:245-254.
7. Neumann PJ, Cohen JT, Hammitt JK, et al. (2010) Willingness-topay for predictive tests with no immediate treatment implications: A survey of US residents. Health Econ [Epub ahead of print]; PMID: 21190163. DOI: 10.1002/hec.1704.
8. Neumann PJ, Hammitt JK, Mueller C, et al. (2001) Public attitudes about genetic testing for Alzheimer's disease. Health Aff 20:252-264. (Pubitemid 33710358)
9. Olsen J (2001) Theory vs. practice: A review of willingness to pay in health and healthcare. Health Econ 10:39-52.
10. Peterson EA, Milliron KJ, Lewis KE, et al. (2002) Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 11: 79-87. (Pubitemid 34118316)
11. Roberts JS, LaRusse SA, Katzen H, et al. (2003) Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer's Disease. Alzheimer Dis Assoc Disord 17:86-93. (Pubitemid 36736842)
12. Szymaniak JM, Christensen KD, Uhlmann WR, et al. (2009) A condensed genetic counseling approach for Alzheimer's disease susceptibility testing: What is the psychological impact? J Genet Couns 18:628.
13. Wagner TH, Hu TW, Dueñ as GV, et al. (2001) Does willingness to pay vary by race/ethnicity? an analysis using mammography among low-income women. Health Policy 58: 275-288. (Pubitemid 32964706)
14. Whynes DK, Wolsetnholme JL, Frew E (2004) Evidence of range bias in contingent valuation payment scales. Health Econ 13:183-190. (Pubitemid 38208179)
15. Yasunaga H, Ide H, Imamura T, Ohe K (2006) Benefit evaluation of mass screening for prostate cancer: Willingness-to-pay measurement using contingent valuation. Urology 68:1046-1050. (Pubitemid 44755438)
16. Zick CD, Mathews C, Roberts JS, et al. (2005) Genetic susceptibility testing for Alzheimer's disease and its impact on insurance behavior. Health Aff 24:483-490. (Pubitemid 40528968)
17. Amsen D, Spilianakis CG, Flavell RA (2009) How are T(H)1 and T(H)2 effector cells made? Curr Opin Immunol 21:153-160.
18. Bai J, Lin M, Zeng X, et al. (2008) Association of polymorphisms in the human IFN-gamma and IL-4 gene with oral lichen planus: A study in an ethnic Chinese cohort. J Interferon Cytokine Res 28:351-358. (Pubitemid 351929934)
19. Bochud PY, Sinsimer D, Aderem A, et al. (2009) Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy. Eur J Clin Microbiol Infect Dis 28:1055-1065.
20. Chatterjee A, Rathore A, Dhole TN (2009) Association of IL-4 589 C/T promoter and IL-4RalphaI50V receptor polymorphism with susceptibility to HIV-1 infection in North Indians. J Med Virol 81:959-965.
21. Fafutis-Morris M, Guillen-Vargas CM, Navarro-Fierro S, et al. (1999) Serum IL-1ra is elevated in lepromatous leprosy patients. Int J Lepr Other Mycobact Dis 67:287-291. (Pubitemid 29536459)
22. Forno C, Häusermann P, Hatz C, et al. (2010) The difficulty in diagnosis and treatment of leprosy. J Travel Med 17:281-283.
23. Ghirelli C, Zollinger R, Soumelis V (2010) Systematic cytokine receptor profiling reveals GM-CSF as a novel TLR-independent activator of human plasmacytoid predendritic cells. Blood 115:5037-5040.
24. Iyer A, Hatta M, Usman R, et al. (2007) Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin- 6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin Exp Immunol 150:210-216. (Pubitemid 47609563)
25. Kaji R, Kiyoshima-Shibata J, Nagaoka M, et al. (2010) Bacterial teichoic acids reverse predominant IL-12 production induced by certain lactobacillus strains into predominant IL-10 production via TLR2-dependent ERK activation in macrophages. J Immunol 184:3505-3513.
26. Kelso A (1998) Cytokines: Principles and prospects. Immunol Cell Biol 76:300-317. (Pubitemid 28352760)
27. Kim YK, Pyo CW, Choi HB, et al. (2007) Associations of IL-2 and IL-4 gene polymorphisms with psoriasis in the Korean population. J Dermatol Sci 48:133-139.
28. Kubo M, Yamashita M, Abe R, et al. (1999) CD28 costimulation accelerates IL-4 receptor sensitivity and IL-4-mediated Th2 differentiation. J Immunol 163:2432-2442. (Pubitemid 29399162)
29. Ma F, Liu X, Li D, et al. (2010) MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolin-mediated IL-10 mRNA degradation. J Immunol 184:6053-6059.
30. Matsuzaki J, Tsuji T, Imazeki I, et al. (2005) Immunosteroid as a regulator for Th1/Th2 balance: Its possible role in autoimmune diseases. Autoimmunity 38:369-375. (Pubitemid 41358667)
31. Montoya D, Modlin RL (2010) Learning from leprosy: Insight into the human innate immune response. Adv Immunol 105:1-24
32. Nakashima H, Miyake K, Inoue Y, et al. (2002) Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immunol 3:107-109. (Pubitemid 38961117)
33. Ostuni R, Zanoni I, Granucci F (2010) Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci 67: 4109-4134.
34. Paul WE (1991) Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77:1859-1870.
35. Paul WE, Zhu J (2010) How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 10: 225-235.
36. Pawlik A, Wrzesniewska J, Florczak M, et al. (2005) The-590 IL-4 promoter polymorphism in patients with rheumatoid arthritis. Rheumatol Int 26:48-51. (Pubitemid 41531514)
37. Ridley DS, Jopling WH (1966) Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 34:255-273.
38. Rosenwasser LJ, Klemm DJ, Dresback JK, et al. (1995) Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 25(Suppl 2):74-78.
39. Salgame P, Abrams JS, Clayberger C, et al. (1991) Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279-282. (Pubitemid 21917341)
40. Scarel-Caminaga RM, Trevilatto PC, Souza AP, et al. (2002) Frequencies of the - 330(T/G) IL-2 and -590(T/C) IL-4 gene polymorphisms in a population from southeastern Brazil. Eur J Immunogenet 29:293-296. (Pubitemid 34779666)
41. Schwarz MJ, Kronig H, Riedel M, et al. (2006) IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256:72-76.
42. Scollard DM, Adams LB, Gillis TP, et al. (2006) The continuing challenges of leprosy. Clin Microbiol Rev 19:338-381.
43. Vercelli D, Jabara HH, Lauener RP, et al. (1990) IL-4 inhibits the synthesis of IFN-gamma and induces the synthesis of IgE in human mixed lymphocyte cultures. J Immunol 144: 570-573. (Pubitemid 20036085)
44. Wu J, Lu Y, Ding YB, et al. (2009) Promoter polymorphisms of IL2, IL4, and risk of gastric cancer in a high-risk Chinese population. Mol Carcinog 48:626-632.
45. Yamamura M, Uyemura K, Deans RJ, et al. (1991) Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 254:277-279. (Pubitemid 21917340)
46. Yu HH, Liu PH, Lin YC, et al. (2010) Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosu in Chinese patients. Lupus 19:1219-1228.